Metropolitan Life Insurance Company (MetLife)’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-5,844
| Closed | -$1.26M | – | 285 |
|
|
2024
Q1 | $1.26M | Sell |
5,844
-55
| -0.9% | -$12.9K | 0.05% | 290 |
|
|
2023
Q4 | $1.53M | Sell |
5,899
-93
| -2% | -$22.8K | 0.07% | 234 |
|
|
2023
Q3 | $1.54M | Sell |
5,992
-316
| -5% | -$84.5K | 0.08% | 215 |
|
|
2023
Q2 | $1.8M | Sell |
6,308
-133
| -2% | -$39.6K | 0.09% | 197 |
|
|
2023
Q1 | $1.79M | Sell |
6,441
-1,729
| -21% | -$478K | 0.09% | 197 |
|
|
2022
Q4 | $2.26M | Sell |
8,170
-469
| -5% | -$132K | 0.1% | 193 |
|
|
2022
Q3 | $2.31M | Sell |
8,639
-182
| -2% | -$38.7K | 0.11% | 178 |
|
|
2022
Q2 | $1.8M | Sell |
8,821
-244
| -3% | -$49.9K | 0.08% | 241 |
|
|
2022
Q1 | $1.91M | Sell |
9,065
-7,713
| -46% | -$1.68M | 0.07% | 267 |
|
|
2021
Q4 | $4.03M | Sell |
16,778
-566
| -3% | -$146K | 0.05% | 279 |
|
|
2021
Q3 | $4.91M | Sell |
17,344
-779
| -4% | -$255K | 0.07% | 215 |
|
|
2021
Q2 | $6.28M | Sell |
18,123
-2,902
| -14% | -$879K | 0.09% | 179 |
|
|
2021
Q1 | $5.88M | Sell |
21,025
-1,335
| -6% | -$360K | 0.09% | 179 |
|
|
2020
Q4 | $5.48M | Sell |
22,360
-1,991
| -8% | -$514K | 0.08% | 190 |
|
|
2020
Q3 | $6.91M | Sell |
24,351
-1,819
| -7% | -$507K | 0.12% | 144 |
|
|
2020
Q2 | $7M | Sell |
26,170
-3,706
| -12% | -$1.11M | 0.12% | 143 |
|
|
2020
Q1 | $9.45M | Sell |
29,876
-496
| -2% | -$151K | 0.19% | 97 |
|
|
2019
Q4 | $9.01M | Sell |
30,372
-413
| -1% | -$115K | 0.14% | 125 |
|
|
2019
Q3 | $7.17M | Sell |
30,785
-7,499
| -20% | -$1.75M | 0.12% | 149 |
|
|
2019
Q2 | $8.95M | Buy |
38,284
+1,438
| +4% | +$332K | 0.15% | 116 |
|
|
2019
Q1 | $8.71M | Sell |
36,846
-2,133
| -5% | -$672K | 0.16% | 110 |
|
|
2018
Q4 | $11.7M | Sell |
38,979
-93
| -0.2% | -$29.7K | 0.23% | 76 |
|
|
2018
Q3 | $13.8M | Sell |
39,072
-2,821
| -7% | -$971K | 0.23% | 75 |
|
|
2018
Q2 | $12.2M | Buy |
41,893
+14,692
| +54% | +$4.13M | 0.2% | 88 |
|
|
2018
Q1 | $7.45M | Sell |
27,201
-14,317
| -34% | -$4.44M | 0.11% | 150 |
|
|
2017
Q4 | $13.2M | Sell |
41,518
-67,322
| -62% | -$21.6M | 0.18% | 83 |
|
|
2017
Q3 | $34.1M | Sell |
108,840
-2,388
| -2% | -$707K | 0.21% | 83 |
|
|
2017
Q2 | $30.2M | Sell |
111,228
-3,987
| -3% | -$1.05M | 0.21% | 91 |
|
|
2017
Q1 | $31.5M | Sell |
115,215
-2,367
| -2% | -$669K | 0.22% | 84 |
|
|
2016
Q4 | $33.3M | Sell |
117,582
-4,042
| -3% | -$1.2M | 0.24% | 76 |
|
|
2016
Q3 | $38.1M | Sell |
121,624
-1,479
| -1% | -$438K | 0.28% | 66 |
|
|
2016
Q2 | $29.8M | Sell |
123,103
-1,240
| -1% | -$327K | 0.22% | 84 |
|
|
2016
Q1 | $32.4M | Sell |
124,343
-3,785
| -3% | -$1,000K | 0.25% | 75 |
|
|
2015
Q4 | $39.3M | Sell |
128,128
-8,710
| -6% | -$2.5M | 0.3% | 61 |
|
|
2015
Q3 | $39.9M | Sell |
136,838
-2,380
| -2% | -$786K | 0.29% | 64 |
|
|
2015
Q2 | $56.2M | Buy |
139,218
+1,167
| +0.8% | +$468K | 0.4% | 45 |
|
|
2015
Q1 | $58.3M | Sell |
138,051
-2,532
| -2% | -$998K | 0.43% | 43 |
|
|
2014
Q4 | $47.7M | Sell |
140,583
-490
| -0.3% | -$159K | 0.33% | 57 |
|
|
2014
Q3 | $46.7M | Sell |
141,073
-2,845
| -2% | -$938K | 0.34% | 54 |
|
|
2014
Q2 | $45.4M | Sell |
143,918
-6,214
| -4% | -$1.87M | 0.31% | 55 |
|
|
2014
Q1 | $45.9M | Sell |
150,132
-2,212
| -1% | -$702K | 0.32% | 57 |
|
|
2013
Q4 | $42.6M | Sell |
152,344
-3,807
| -2% | -$985K | 0.3% | 63 |
|
|
2013
Q3 | $37.6M | Sell |
156,151
-1,072
| -0.7% | -$240K | 0.29% | 65 |
|
|
2013
Q2 | $33.8M | Buy |
+157,223
| New | +$33.6M | 0.27% | 68 |
|
Other funds holding BIIB
Metropolitan Life Insurance Company (MetLife)'s BIIB Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Biogen (BIIB) in Q2 2024, closing a stake of 5,844 shares — an estimated $1.26M sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in BIIB in Q2 2013 and held it in 44 quarters. The position peaked at $58.3M in Q1 2015. 944 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 5,844 Biogen shares in Q2 2024, an estimated $1.26M.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Biogen in Q2 2013 and held it in 44 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Biogen position peaked at $58.3M in Q1 2015.
- 944 funds tracked by Wall St. Rank held Biogen as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.